LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
This randomized, open-label, phase III study will be performed in patients with recurrent and/or metastatic head and neck cancer which has progressed after platinum-based therapy. The objectives of this trial are to compare the efficacy and safety of afatinib versus methotrexate.
Epistemonikos ID: c361c47b4ff412d38d4a6f5c9c761197c6405f73
First added on: May 11, 2024